About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT00718848

Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease

Background: Recent data indicate that home nocturnal hemodialysis (8 hours of hemodialysis at home for 5-6 nights per week) may have substantial cardiovascular benefits, including regression of left v...

Lead sponsor: Unity Health Toronto•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Unity Health Toronto

Collaborators

Canadian Institutes of Health Research (CIHR)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•adult patients currently treated with conventional hemodialysis for \> 6 months

Exclusion Criteria

•acute coronary syndrome or coronary revascularization (percutaneous coronary intervention, coronary bypass surgery) within the past 6 months
•uncontrolled hypertension (systolic blood pressure \> 200 mmHg, or diastolic blood pressure \> 120 mmHg)
•severe heart failure (New York Heart Association functional class IV)
•chronic atrial fibrillation
•serious co-morbidity (e.g. cancer) with a life expectancy of less than 1 year
•pregnancy
•patient refusal to undergo baseline CMR
•contraindications to CMR (e.g. pacemaker, implantable cardiac defibrillator)
•inability to provide informed consent

Related studies

RECRUITINGPhase 4

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055 · Hypertension, Left Ventricular Hypertrophy

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NCT04634916 · Kidney Disease, End-Stage, End-stage Renal Disease, and more

RECRUITINGPhase 3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472 · Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, and more

Imaging Histone Deacetylase in the Heart

NCT03549559 · Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, and more

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

NCT07263204 · Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 14, 2015Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment67

Start dateJul 2008

Last updatedOct 14, 2015

Condition

End-stage Renal Disease Left Ventricular Hypertrophy

Locations shown

St. Paul's Hospital

Vancouver, British Columbia

St. Michael's Hospital

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 14, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions